Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Blood Cancer Discovery|July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell LymphomasFederico Stella, Annalisa Chiappella, Beatrice Casadei, et al.
Open Forum Infectious Diseases|May 5, 2025
The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome After Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir ProphylaxisCorrado Girmenia, Patrizia Chiusolo, Giovanni Marsili, et al.
Cancer|March 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life settingJacopo Nanni, Irene Azzali, Cristina Papayannidis, et al.
Transplantation and Cellular Therapy|January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE StudyFederico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Transplantation and Cellular Therapy|February 25, 2026
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE StudyAngelica Barone, Federico Stella, Silva Ljevar, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
Bone Marrow Transplantation|December 24, 2025
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithmAlexandros Rampotas, Jose Maria Aspa-Cilleruelo, Linda Koster, et al.
Bone Marrow Transplantation|September 3, 2022
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamideJacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
Pageof 20